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Background/aim: To investigate whether spontaneous preterm labor (PTL) with intact membranes is associated with changes in
maternal serum prohepcidin concentrations.
Materials and methods: The study consisted of patients with spontaneous PTL with intact membranes (n = 25), a control group of
healthy pregnant women between the 24th and 37th gestational weeks (n = 22), and uncomplicated term pregnancies in spontaneous
labor (n = 19). Blood samples were collected from patients at the time of clinical diagnosis. Levels of prohepcidin, hemoglobin, serum
ferritin, serum iron, unsaturated iron binding capacity, total iron binding capacity, transferrin and transferrin saturation, C reactive
protein, and interleukin-6 were measured.
Results: Patients with spontaneous PTL had significantly lower maternal serum prohepcidin concentrations than term delivery and
control subjects.
Conclusion: Maternal serum prohepcidin concentration is lower in patients with spontaneous PTL compared to term delivery and control
subjects. This suggests that measuring maternal serum prohepcidin concentrations in PTL may be a feasible method for understanding
etiologic causes of spontaneous preterm delivery, but, before suggesting this as a course of action, low levels of prohepcidin in patients
with PTL need to be more fully investigated.
Key words: Spontaneous preterm labor, term pregnancy, prohepcidin

1. Introduction
The birth of a baby prior to 37 weeks of gestation is
defined as a preterm birth and this complicates 5%–10%
of all deliveries. Despite advances in medicine, the cause of
preterm birth is in many situations elusive and unknown
(1). Many factors appear to be associated with the
etiology; there is overwhelming evidence that intrauterine
infection and inflammation play an important role in the
pathogenesis of spontaneous preterm labor (PTL). It is one
of the major causes of perinatal mortality and morbidity,
and a significant cost factor in healthcare. Early diagnosis
of subclinical infection and inflammation may therefore
aid clinicians in instigating interventions focusing on
avoiding such adverse outcomes (2–5).
Hepcidin, a small peptide hormone produced by
the liver, has a significant role in the regulation of iron
homeostasis (6,7). It acts not only in iron regulation but
also in host defense. Recently, hepcidin has been reported
as a type 2 acute phase reactant. During infection and
inflammation, hepcidin synthesis is markedly increased by
* Correspondence: eakeskin@hotmail.com
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a mechanism that is independent of erythropoietic activity
(8–11).
Prohepcidin, another 84-amino acid peptide, is the
precursor of the active hepcidin. Previous studies have
shown that inflammatory stimulation of liver hepcidin
synthesis is mediated by macrophage production of
cytokines interleukin (IL)-6 and IL-1 in humans and mice
(10,12). It has also been reported that serum prohepcidin
levels were increased in neonatal sepsis as an acute phase
antimicrobial peptide (13). Several studies have reported
about the association between maternal inflammation
and preterm deliveries. Different maternal serum and
vaginal inflammatory markers such as C reactive protein
(CRP), activin, inhibin, relaxin, and IL-6 were studied for
predicting preterm births (14–17). These studies led us to
consider that if serum prohepcidin is accepted as an acute
phase reactant, the level of this peptide hormone might
be changed in preterm delivery. Maternal prohepcidin
concentration has been investigated in uncomplicated
pregnancy, but the level of this peptide hormone in
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complicated pregnancies, such as cases of PTL, has not
been investigated yet (18).
The aim of the present study is to investigate maternal
serum prohepcidin levels in preterm pregnant women
and to give new insight on the relation between maternal
prohepcidin concentration and spontaneous PTL.
2. Materials and methods
2.1. Study design and population
This cross-sectional study was performed at the Turgut
Özal University Obstetrics Unit in Ankara, Turkey,
between September 2008 and September 2009. The study
was approved by the ethics committee of the university
and informed consent was obtained from the subjects.
This study included women in the following groups:
patients with spontaneous PTL with intact membranes
(n = 25), healthy pregnant women between the 24th and
37th gestational weeks as a control group (n = 22), and
uncomplicated term pregnancies in spontaneous labor (n
= 19).
Women were considered to have had an uncomplicated
term pregnancy if they did not have any medical,
obstetrical, or surgical complications and delivered a
normal neonate at term (37–41 weeks of gestation) that
was appropriately grown for the gestational age (19).
Spontaneous PTL was defined as the presence of
regular uterine contractions occurring at a frequency of at
least 2 every 10 min and associated with a cervical change
that required hospitalization before 37 completed weeks of
gestation.
The control group consisted of 22 healthy pregnant
women from 24 to 37 gestation weeks who had no risk
factors for preterm delivery and who underwent regular
gynecological examinations.
The inclusion criteria for the women recruited for
this study were: singleton pregnancy, hospitalization for
PTL, hospitalization for spontaneous term labor, intact
membranes.
Women with the following criteria were excluded:
rupture of membranes, chorioamnionitis, fetal distress
requiring extraction, fetal malformation, a maternal
disorder requiring pregnancy termination, advanced labor
(3 cm of cervical dilatation with uterine contractions).
All subjects had been given a daily supplement of 100
mg of iron as ferrous gluconate from 16 weeks of gestation
until delivery. Microscopic examinations of cultures of
urine and cervicovaginal secretions were carried out for
all patients. Urinary infection and bacterial vaginosis were
treated according to culture results.
Serum samples collected from all subjects for
progesterone-induced blocking factor and cytokine
determinations were aliquoted and kept at −80 °C until
used. Blood samples were collected from preterm and

term patients at the time of clinical diagnosis. Each blood
sample was analyzed for complete blood count, serum iron
and ferritin concentrations, iron binding capacity, and
prohepcidin level.
Levels of prohepcidin (ng/mL) were measured with
an enzyme-linked immunosorbent assay (ELISA; DRG
Instruments, Marburg, Germany). Hemoglobin (g/dL)
was analyzed with a Beckman Coulter LH 750 hematology
analyzer. Serum ferritin (ng/mL) was measured with an
electrochemiluminescence assay (E170, Roche). Serum
iron (µg/dL) and unsaturated iron binding capacity
(UIBC) (µg/dL) were measured with a Roche Cobas
Integra 800 autoanalyzer. Total iron binding capacity
(TIBC) (µg/dL) values were calculated automatically
from the sum of serum iron and UIBC, both of which
were determined by colorimetric methods. Transferrin
saturation was calculated directly as (Fe / TIBC) × 100
(%). Transferrin (mg/dL) and CRP (mg/L) were analyzed
with a nephelometer (Beckman Coulter, IMMAGE
immunoassay). IL-6 (pg/mL) was measured with a Siemens
IMMULITE 2000 chemiluminescence immunoassay
system.
2.2. Statistical analysis
Data analysis was performed using SPSS 11.5 for Windows
(SPSS Inc., Chicago, IL, USA). Whether the continuous
variables were normally distributed or not was determined
by using the Shapiro–Wilk test. The Levene test was
applied for the evaluation of the homogeneity of variances.
Data are shown as mean ± standard deviation or median
(minimum–maximum) as appropriate.
Means were compared by one-way ANOVA and the
Kruskal–Wallis test was applied for the comparisons of
the median values. When the P-value was statistically
significant, post hoc Tukey or nonparametric multiple
comparison tests were used to determine which groups
differed from which others. Degrees of association
between continuous variables were evaluated by either
Pearson’s product moment or Spearman’s rank correlation
test. A P-value of less than 0.05 was considered statistically
significant.
3. Results
3.1. Clinical findings
There were no statistically significant differences between
the groups of patients in terms of age, gravida, parity,
or body mass index (BMI), but there was a statistically
significant difference in terms of gestational age at delivery
(P > 0.05) and birth weight of newborns (P > 0.05) (Table
1). Demographic and clinical characteristics of patients are
listed in Table 1.
3.2. Maternal plasma prohepcidin levels
Maternal plasma prohepcidin levels were measurable in
all samples evaluated. As shown in the Figure, maternal
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Table 1. Demographic and clinical characteristics of women with term delivery, patients with PTL and intact membranes,
and control group.
PTL (n = 19)

Control (n = 22)

Aged (years)

27.8 ± 4.72

27.8 ± 3.59

27.9 ± 5.44

NS

1 (1–3)

2 (1–4)

2 (1–4)

NS

1 (1–2)

1 (1–3)

2 (1–3

NS

Body mass index (kg/m )

26.5 ± 1.81

27.2 ± 2.13

27 ± 1.48

NS

GA at delivery (weeks)

35.1 (25.4–36.5)

32.6 (27.4–36.5)

39.6 (37.3–41.4)

<0.05

Birth weight (g)

2440 (730–3610)

2310 (890–3450)

3420 (2930–3750)

< 0.05

2

plasma prohepcidin concentrations were significantly (P
< 0.05) lower in women who delivered preterm [52.4 (39–
242.3) ng/mL] than in controls [77.1 (36.3–149.1) ng/mL]
and those who progressed to spontaneous term delivery
[70 (34.4–116.7) ng/mL].
Serum Hb, iron, TIBC, transferrin saturation, and
ferritin concentration were similar between groups.
However, CRP, and IL-6 levels were higher in term delivery
and PTL groups compared to the control group (Table 2).
No correlation was detected between maternal serum
hepcidin concentration and maternal age, gravida, parity,
gestational age, or BMI. Additionally, no correlation was
detected between maternal serum hepcidin concentration
and serum iron parameters in the groups.
160
140
120
Hepcidin (ng/mL)

P

Gravida
Parity

100
80
60
40
20
0
Term Delivery

PTL

Control

Figure. Maternal serum prohepcidin concentrations in normal
term delivery, PTL, and control groups. Note that maternal serum
prohepcidin concentration is elevated in both term delivery and
control groups.
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Term delivery (n = 25)

4. Discussion
The present study is the first trial to investigate maternal
plasma prohepcidin concentration in women with
preterm labor. The only limitation was the study size.
According to our results, patients with spontaneous PTL
had a significantly lower median maternal prohepcidin
concentration than the term delivery patients and
the control group. In addition, no correlation was
detected between median maternal plasma prohepcidin
concentration and iron parameters in the groups.
These results are not consistent with our expectations.
When we designed this study, because prohepcidin
has been shown to be a type II acute phase protein like
other inflammatory markers, we thought it could be
used to predict preterm labor. However, contrary to our
expectations, maternal prohepcidin concentration was
detected to be lower in PTL patients compared to term and
control patients. This may be due to the iron-related effect
of hepcidin. Iron is an essential element that is required
for growth and development in all living organisms. At the
same time, iron is dangerous to cells because of its ability
to catalyze free radical generation. Oxidative damage
caused by free radicals is thought to be causally related
to numerous diseases, such as atherosclerosis, diabetes,
cancer, and neurodegenerative diseases (20).
Different maternal iron parameters and their
relationships with several obstetrical syndromes such as
preeclampsia, intrauterine growth retardation, and PTL
have been investigated in studies. Iron deficiency anemia
in pregnancy is a known risk factor for preterm delivery
(21).
Iron transport increases significantly during pregnancy
due to the high growth rates of the fetus and placenta and
the expansion of the maternal red blood cell mass. The
availability of iron for the fetus depends on maternal iron
stores and intestinal absorption of iron (22). Transport of
iron via the placenta is usually sufficient to meet the needs
of the fetus, except in cases of severe iron deficiency (23).
There is a little evidence that hepcidin is also involved in
transplacental iron transfer, but its role in this process is
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Table 2. Serum concentrations of maternal iron parameters and acute phase reactants (mean ± SD).
PTL

Control

Term delivery

Hepcidin (ng/mL)

52.4 (39–242.3)

77.1 (36.3–149.6)

70 (34.4–116.7)

Hemoglobin (g/dL)

12 ± 1

11.9 ± 1.04

11.1 ± 3.38

NS

Serum iron (µg/dL)

53 (27–470)

68 (25–539)

56 (28–214)

NS

TIBC (µg/dL)

528 ± 66.94

472 ± 85.92

504.3 ± 65.04

NS

Serum ferritin (ng/mL)

18 (5.8–54)

17.5 (8–47)

20 (7.3–44)

NS

Transferrin (mg/dL)

402 (300–543)

348.5 (252–539)

457.5 (339–5334)

<0.05

Transferrin saturation

13 (6.5–34)

15 (6–31)

13.1 (7.9–18.3)

NS

CRP (mg/L)

6.8 (2–93)

4.7 (2–16)

9 (1–76)

<0.05

IL-6 (pg/mL)

2.7 (1–92)

1 (1–61)

3.6 (1–181)

<0.05

not fully understood. The general role of prohepcidin is to
be a negative regulator of iron export via ferroportin and
therefore to prevent the iron efflux from cells (24).
Hepcidin is mainly secreted by the liver, but smaller
amounts of hepcidin mRNA are also expressed in other
organs, e.g., the heart, brain, and lungs, and also in the
placenta (25,26). Generally, iron carried by transferrin in
maternal serum is bound to the transferrin receptor on the
placental cells, and both are endocytosed into the placental
cells. Iron transferred through the placental cells is then
mediated through ferroportin to the fetal circulation
(27). The amount of ferroportin in the cell membrane is
regulated by hepcidin (28).
Maternal prohepcidin levels have been studied in
normal pregnancy (18), but the level of plasma prohepcidin
has not been investigated before in spontaneous PTL. In
preterm delivery, prohepcidin levels have been detected
in maternal serum and decreased levels of maternal
prohepcidin may adversely influence iron homeostasis in
the placenta and cause an iron overload in the placenta.
The placental burden of iron can be a reason for hypoxiainduced preterm delivery. In mice models, hepcidin
gene expression is decreased in anemia and in hypoxic
conditions (11).
Hereditary hemochromatosis is the most well-known
disease related to hepcidin. In hereditary hemochromatosis,
dietary iron absorption is increased above the amount
required to replace losses, and excess iron is deposited in
the liver, endocrine glands, heart, and skin (29).
Eventually, the iron-overloaded organs suffer tissue
damage, presumably through the iron-catalyzed generation
of reactive oxygen species. A similar relationship may
be true for spontaneous PTL, e.g., acquired maternal
prohepcidin insufficiency causes iron overload in the
placenta and that causes damage to the placenta.
Hepcidin
expression
decreases
progressively
throughout pregnancy, reaching its lowest level just before

P

parturition, and then approaches normal levels soon after
birth. Decreases in the level of hepcidin probably trigger
PTL. Even so, it is not known what the normal level of
maternal serum prohepcidin is in the third trimester; we
compared maternal prohepcidin levels and detected low
levels of maternal serum prohepcidin in the spontaneous
PTL group. However, we are not sure that these low levels
of maternal serum prohepcidin are a reason for, or a
consequence of, spontaneous PTL.
Some studies have reported significant correlations
between maternal serum prohepcidin concentration and
serum iron status measurements (30,31), but there are
also studies showing opposite findings (32,33). We also
did not show any correlation between maternal serum
prohepcidin levels and iron parameters in the groups.
However, maternal serum IL-6 and CRP levels were
detected to be increased in both term and PTL patients
compared to the control group. Similarly, maternal serum
iron binding capacity and transferrin levels were detected
as higher in both term and PTL patients compared to the
control group. This is probably related to the effect of labor
on inflammatory markers.
Prohepcidin is an inactive prohormone from which
active hepcidin is cleaved (18). Reliable immunoassays for
hepcidin have been recently reported but require further
validation before their use can be generalized (25,34). Thus,
many studies have used prohepcidin ELISA measurement
in iron homeostasis studies (35).
In conclusion, our results show that inappropriately
low maternal serum prohepcidin levels in pregnant
women may be the cause of iron-mediated tissue damage
through placental iron loading leading to subclinical fetal
hypoxia, which could trigger PTL. Whatever the role of
the decreased levels of circulating maternal prohepcidin
concentrations, the clinical usefulness of maternal serum
prohepcidin measurement for predicting the occurrence
of PTL merits further consideration.
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